MINOCA as the first presentation of JAK2 V617F-positive polycythaemia rubra vera

被引：0
|
作者：
Rus, M. R. Mohamed [1 ]
Suhaimi, A. Mohd [1 ]
Zulkufli, M. R. [1 ]
Kassim, N. Mohd [1 ]
Rozali, N. [1 ]
Hussin, F. R. [1 ]
Shahril, N. S. [2 ]
机构：
[1] Hosp Angkatan Tentera Tuanku Mizan, Dept Med, Cardiol Unit, Kuala Lumpur, Malaysia
[2] Hosp Putrajaya, Dept Med, Putrajaya, Malaysia
来源：
INTERNATIONAL JOURNAL OF CARDIOLOGY | 2022年 / 369卷
关键词：
D O I：
10.1016/j.ijcard.2022.10.112
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
85
引用
收藏
页码：41 / 41
页数：1
相关论文
共 50 条
  • [21] Effects of Ruxolitinib on Immune Checkpoint Molecule Expression in JAK2 V617F-Positive Cells
    Fu, Jianzhu
    Cheng, Zhiyong
    Zhang, Lijun
    Wen, Xingchu
    Hao, Jianxue
    CLINICAL LABORATORY, 2024, 70 (10) : 1897 - 1907
  • [22] The relevance of HLA class II genes in JAK2 V617F-positive myeloproliferative neoplasms
    Shivarov, Velizar
    Tsvetkova, Gergana
    Hadjiev, Evgueniy
    Ivanova, Milena
    HUMAN IMMUNOLOGY, 2023, 84 (03) : 199 - 207
  • [23] JAK2 V617F-positive essential thrombocythemia in a patient with Klinefelter syndrome: a case report
    Yhim, Ho-Young
    Kim, Hee Sun
    Sohn, Ji-Youn
    Song, Min-Ju
    Lee, Na-Ri
    Song, Eun-Kee
    Choi, Sam-Im
    Yim, Chang-Yeol
    Kwak, Jae-Yong
    CANCER GENETICS AND CYTOGENETICS, 2010, 198 (02) : 162 - 165
  • [24] Concomitant JAK2 V617F-positive polycythemia vera and BCR-ABL-positive chronic myelogenous leukemia treated with ruxolitinib and dasatinib
    Zhou, A.
    Knoche, E. M.
    Engle, E. K.
    Fisher, D. A. C.
    Oh, S. T.
    BLOOD CANCER JOURNAL, 2015, 5 : e351 - e351
  • [25] Mesenteric venous thrombosis secondary to an unsuspected JAK2 V617F-positive myeloproliferative disorder
    Bourke, M. G.
    Martin, S. T.
    O'Dwyer, M.
    Hanaghan, J.
    Bennani, F.
    Barry, M. K.
    IRISH JOURNAL OF MEDICAL SCIENCE, 2012, 181 (02) : 285 - 287
  • [26] JAK2 V617F impairs hematopoietic stem cell function in a conditional knock-in mouse model of JAK2 V617F-positive essential thrombocythemia
    Li, Juan
    Spensberger, Dominik
    Ahn, Jong Sook
    Anand, Shubha
    Beer, Philip A.
    Ghevaert, Cedric
    Chen, Edwin
    Forrai, Ariel
    Scott, Linda M.
    Ferreira, Rita
    Campbell, Peter J.
    Watson, Steve P.
    Liu, Pentao
    Erber, Wendy N.
    Huntly, Brian J. P.
    Ottersbach, Katrin
    Green, Anthony R.
    BLOOD, 2010, 116 (09) : 1528 - 1538
  • [27] An Open-Label Study of CEP-701 in Patients with JAK2 V617F-Positive Polycythemia Vera and Essential Thrombocytosis
    Moliterno, Alison R.
    Roboz, Gail J.
    Carroll, Martin
    Luger, Selina
    Hexner, Elizabeth
    Bensen-Kennedy, Debra M.
    BLOOD, 2008, 112 (11) : 44 - 44
  • [28] MECHANISMS DRIVING THROMBOPOIETIN RECEPTOR DOWN MODULATION IN JAK2 V617F-POSITIVE MYELOPROLIFERATIVE NEOPLASMS
    Constantinescu, S.
    Pecquet, C.
    Diaconu, C.
    Staerk, J.
    Girardot, M.
    Royer, Y.
    Defour, J. P.
    Dusa, A.
    Knoops, L.
    Giraudier, S.
    Villeval, J. L.
    Courtoy, P.
    Vainchenker, W.
    HAEMATOLOGICA, 2012, 97 : 372 - 372
  • [29] The diagnosis of Polycythaemia Vera in JAK2V617F and JAK2 exon 12 negative patients-A Local Experience
    Symonds, C.
    Abu-Sitta, A.
    Al-Refaie, F.
    BRITISH JOURNAL OF HAEMATOLOGY, 2019, 185 : 76 - 76
  • [30] The Red Cell Mass (RCM) Value In Polycythaemia Vera Disease In The JAK2 V617F Era
    Al-Jafar, Hassan A.
    Aytoglu, Leena M.
    Loutfi, Issa
    Al-Shemmari, Iman
    Alshemmari, Salem H.
    BLOOD, 2013, 122 (21)
12345